Artículos por temáticas

The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease

Maskery M, Goulding EM, Gengler S, Melchiorsen JU, Rosenkilde MM, Hölscher C.

Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520953041. doi: 10.1177/1533317520953041.

Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies

Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, Pase MP, Himali JJ, Gwen Windham B, Griswold M, Gottesman R, Mosley TH, White L, Guðnason V, Debette S, Beiser AS, Seshadri S, Ikram

Lancet Neurol. 2020 Jan;19(1):61-70. doi: 10.1016/S1474-4422(19)30393-X. Epub 2019 Nov 6.

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease

Yoshida K, Moein A, Bittner T, Ostrowitzki S, Lin H, Honigberg L, Jin JY, Quartino A.

Alzheimers Res Ther. 2020 Jan 22;12(1):16. doi: 10.1186/s13195-020-0580-2.

Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease

Behl T, Kaur I, Fratila O, Brata R, Bungau S.

Int J Mol Sci. 2020 Oct 9;21(20):7443. doi: 10.3390/ijms21207443.

Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest)

Richards K, Morrison J, Wang YY, Rangel A, Loera A, Hanlon A, Lozano A, Kovach C, Gooneratne N, Fry L, Allen R.

Res Gerontol Nurs. 2020 Nov 1;13(6):280-288. doi: 10.3928/19404921-20200918-01. Epub 2020 Sep 24.

Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease

Fülöp T, Munawara U, Larbi A, Desroches M, Rodrigues S, Catanzaro M, Guidolin A, Khalil A, Bernier F, Barron AE, Hirokawa K, Beauregard PB, Dumoulin D, Bellenger JP, Witkowski JM, Frost E.

CNS Drugs. 2020 Jul;34(7):673-695. doi: 10.1007/s40263-020-00737-1.

Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers

Gopalan D, Pandey A, Udupa N, Mutalik S.

J Control Release. 2020 Mar 10;319:183-200. doi: 10.1016/j.jconrel.2019.12.034. Epub 2019 Dec 19.

Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum

Dubbelman MA, Jutten RJ, Tomaszewski Farias SE, Amariglio RE, Buckley RF, Visser PJ, Rentz DM, Johnson KA, Properzi MJ, Schultz A, Donovan N, Gatchell JR, Teunissen CE, Van Berckel BNM, Van der Flier

Alzheimers Res Ther. 2020 Oct 29;12(1):138. doi: 10.1186/s13195-020-00706-2.

Synthesis, characterization, and biological studies of chalcone derivatives containing Schiff bases: Synthetic derivatives for the treatment of epilepsy and Alzheimer's disease

Koçyiğit ÜM, Gezegen H, Taslimi P.

Arch Pharm (Weinheim). 2020 Dec;353(12):e2000202. doi: 10.1002/ardp.202000202. Epub 2020 Aug 20.

Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis

Rezabakhsh A, Rahbarghazi R, Fathi F.

Biosens Bioelectron. 2020 Nov 1;167:112511. doi: 10.1016/j.bios.2020.112511. Epub 2020 Aug 17.

Association of Cigarette Smoking With Cerebrospinal Fluid Biomarkers of Neurodegeneration, Neuroinflammation, and Oxidation

Liu Y, Li H, Wang J, Xue Q, Yang X, Kang Y, Li M, Xu J, Li G, Li C, Chang HC, Su KP, Wang F.

JAMA Netw Open. 2020 Oct 1;3(10):e2018777. doi: 10.1001/jamanetworkopen.2020.18777.

Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences

Lombardi G, Pupi A, Bessi V, Polito C, Padiglioni S, Ferrari C, Lucidi G, Berti V, De Cristofaro MT, Piaceri I, Bagnoli S, Nacmias B, Sorbi S.

J Alzheimers Dis. 2020;77(1):203-217. doi: 10.3233/JAD-200119.

Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer's-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3β pathway

Akhtar A, Dhaliwal J, Saroj P, Uniyal A, Bishnoi M, Sah SP.

Inflammopharmacology. 2020 Apr;28(2):385-400. doi: 10.1007/s10787-019-00681-7. Epub 2020 Jan 3.

The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol

Kainuma M, Funakoshi K, Ouma S, Yamashita KI, Ohara T, Yoshiiwa A, Murata M, Tsuboi Y.

Medicine (Baltimore). 2020 Sep 18;99(38):e22370. doi: 10.1097/MD.0000000000022370.

A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain

Li S, Selkoe DJ.

J Neurochem. 2020 Sep;154(6):583-597. doi: 10.1111/jnc.15007. Epub 2020 Apr 5.